Association of glucagon-like peptide-1 receptor agonist use with clinical outcomes in patients with rheumatoid arthritis and type 2 diabetes.

Key Points

• To examine the association of GLP-1 receptor agonists with clinical outcomes in patients having both rheumatoid arthritis and type 2 diabetes.
• Analyzed clinical data from patients with rheumatoid arthritis and type 2 diabetes
• Compared outcomes of GLP-1 receptor agonists and DPP-4 inhibitors
• Assessed mortality, kidney events, and hospitalization rates
• GLP-1 receptor agonist therapy linked to 32% lower mortality
• Associated with 11% fewer kidney events
• Led to 8% fewer hospitalizations compared to DPP-4 inhibitors

Abstract